Niagen Bioscience (NASDAQ: NAGE) has announced that its board of directors has authorized an increase to the company’s previously disclosed share repurchase program, raising the total authorization from $10 million to $20 million of outstanding common stock.
Through March 17, 2026, Niagen has repurchased approximately $2.6 million of its common stock under the share repurchase program. Additional information regarding share repurchases will be reported in the company’s periodic reports filed with the SEC.
In a statement, Rob Fried, CEO of Niagen commented, “The recent repurchase of our common stock and $10 million increase in our program reflect the conviction we have in our strategy and long-term value. We will continue to take advantage of the disconnect between NAGE’s market valuation and the underlying strength of our business opportunistically.”
